Document is current
Any future updates will be listed below
-
Authors
Galluzzi, Lorenzo https://orcid.org/0000-0003-2257-8500
Smith, Kellie N. https://orcid.org/0000-0002-6295-8930
Liston, Adrian https://orcid.org/0000-0002-6272-4085
Garg, Abhishek D. https://orcid.org/0000-0002-9976-9922
- License Information
-
More Information
Article History
Accepted: 12 March 2025
First Online: 11 April 2025
Competing interests
: A.D.G. received consulting/advisory/lecture honoraria or R&D contracts from Boehringer Ingelheim (Germany), Miltenyi Biotec (Germany), Novigenix (Switzerland), Sotio (Czech Republic) and IsoPlexis (USA). L.G. holds or has held research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting or advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, AbbVie and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. K.N.S. has received honoraria from Adaptive Biotechnologies and Illumina, Inc., has received research support from AbbVie, Bristol Myers Squibb and AstraZeneca, holds several patents related to the MANAFEST technology and TCR discovery, and is a scientific founder of Clasp Therapeutics. The other authors declare no competing interests.
